HCA Healthcare (HCA) closed at $327.25 in the latest trading session, marking a -0.16% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.74%. Meanwhile, the Dow experienced a drop of 0.01%, and the technology-dominated Nasdaq saw an increase of 1.68%.Coming into today, shares of the hospital operator had gained 1.82% in the past month. In that same time, the Medical sector lost 4.72%, while the S&P 500 gained 0.8%.Investors will be eagerly watching for the performance ...

HCA Healthcare, Inc. (HCA) is aided by growing surgery cases, acquisitions of healthcare facilities and solid operating cash flows. A positive business outlook for 2024 reinforces investors’ confidence in the stock.Top Zacks Rank & Upbeat Price PerformanceHCA Healthcare currently carries a Zacks Rank #2 (Buy).The stock has gained 21.2% year to date compared with the industry’s 18.7% growth. The Zacks Medical sector has rallied 2.2% and the S&P 500 composite has risen 9.2% in the same time frame. Image Sourc ...

HCA Healthcare (HCA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this hospital operator have returned +2.1%, compared to the Zacks S&P 500 composite's +1.7% change. During this period, the Zacks Medical - Hospital industry, which HCA falls in, has lost 0.5%. The key question now is: What could be the stock's future direction?Altho ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe ...

HCA Healthcare (HCA) closed the most recent trading day at $328.80, moving +1.12% from the previous trading session. This change outpaced the S&P 500's 1.11% gain on the day. Elsewhere, the Dow saw an upswing of 0.8%, while the tech-heavy Nasdaq appreciated by 1.24%.The hospital operator's shares have seen an increase of 0.16% over the last month, surpassing the Medical sector's loss of 2.46% and falling behind the S&P 500's gain of 0.48%.The investment community will be closely monitoring the performance o ...

HCA Healthcare (HCA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this hospital operator have returned +4.4% over the past month versus the Zacks S&P 500 composite's +1.5% change. The Zacks Medical - Hospital industry, to which HCA belongs, has gained 4.3% over this period. Now the key question is: Where could the stock be headed in the near term?While media release ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11239 HCA Healthcare, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-3865930 (State or Other Jurisdiction of I ...

Financial Data and Key Metrics Changes - Adjusted EBITDA grew just under 14% in Q4 2023 compared to the prior year, driven by strong revenue growth and solid expense management [13] - Diluted earnings per share, excluding gains on sales, were $5.90, representing a 27% increase over the prior year [30] - For 2024, net income attributable to HCA Healthcare is expected to range between $5.2 billion and $5.6 billion, with diluted earnings per share projected between $19.70 and $21.20 [16][17] Business Line Data and Key Metrics Changes - Same-facility admissions grew 3% year-over-year, equivalent admissions were up 4%, and emergency room visits grew 2% in Q4 2023 [8] - Inpatient and outpatient surgery volumes increased approximately 1%, with cardiac procedures and rehab admissions also showing solid growth [8] - For the full year 2023, same facility admissions grew 3.3%, equivalent admissions grew 4.8%, and emergency room business grew 4.7% [39] Market Data and Key Metrics Changes - Payer mix and acuity levels improved year-over-year, contributing to same-facility revenue growth of 11% in Q4 2023 [8] - Managed care and other admissions grew 6% for the full year on a same-facility basis [39] - Medicare Advantage admissions were roughly up 10% in Q4 2023, consistent with trends throughout the year [57] Company Strategy and Development Direction - The company plans to invest over $2 billion in new capital projects in 2024 to increase capacities and integrate newly acquired facilities [5] - A robust agenda is in place to advance digital capabilities and improve operational management, including integrating revenue cycle and case management functions [9] - The strategic plan includes increasing capital spending to over $5 billion and enhancing the share repurchase program to around $5 billion in 2024 [36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to normal seasonality in volumes and noted strong demand for services across diversified markets [24][30] - The company anticipates modest benefits from the two-midnight rule as it ramps up throughout 2024, although no material adjustments have been factored into the guidance yet [121] - Management highlighted the importance of workforce development and training as a top organizational priority moving into 2024 [35] Other Important Information - Bill Rutherford, the CFO, announced his retirement after 34 years with the company, with Mike Marks set to succeed him [21][48] - The company expects cash flow from operations to range between $9.5 billion and $10 billion for 2024 [18] Q&A Session Summary Question: Inquiry about volumes and seasonality - Management confirmed that normal seasonality was observed in Q4 2023, with strong performance across most business categories [24] Question: Supplemental payments details - Management discussed the complexity of supplemental payments and their impact on revenue, noting benefits from new programs in North Carolina and Florida [25][40] Question: Medicare revenue growth - Medicare Advantage admissions grew roughly 10% in Q4 2023, with expectations for continued strong demand in 2024 [57] Question: Impact of the two-midnight rule - Management indicated it is too early to judge the full impact of the two-midnight rule but expects it to benefit patients and the company over time [29][121] Question: Labor supply and hiring outlook - Management reported improvements in turnover and hiring pipelines, with a focus on creating a supportive environment for staff [140][141] Question: Capital expenditure guidance - The company plans to allocate over $5 billion in capital spending for 2024, maintaining a balanced approach across inpatient and outpatient facilities [36][79]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-11239 HCA Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3865930 (State or other jurisdic ...

HCA Healthcare, Inc. (NYSE:HCA) Q3 2023 Earnings Conference Call October 24, 2023 10:00 AM ET Company Participants Sam Hazen - Chief Executive Officer Bill Rutherford - Chief Financial Officer Frank Morgan - Vice President of Investor Relations Conference Call Participants Kevin Fischbeck - Bank of America A.J. Rice - UBS Ben Hendrix - RBC Capital Markets Gary Taylor - T.D. Cowan Ann Hynes - Mizuho Whit Mayo - Leerink Partners Brian Tanquilut - Jefferies Stephen Baxter - Wells Fargo Pito Chickering - Deutsc ...